



# Pharmacodynamics of Methylprednisolone on *Glucocorticoid Receptor* and *Tyrosine Aminotransferase*



**Alexander Vowinkel**

**SUN ET AL.** DOSE-DEPENDENCE AND REPEATED-DOSE STUDIES FOR RECEPTOR/GENE-MEDIATED PHARMACODYNAMICS OF METHYLPREDNISOLONE ON GLUCOCORTICOID RECEPTOR DOWN-REGULATION AND TYROSINE AMINOTRANSFERASE INDUCTION IN RAT LIVER. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, VOL. 26, NO. 6, 1998

# Methylprednisolone (MPL)


Systematic name: (1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadeca-3,6-dien-5-one

Class: synthetic **glucocorticoid**



# Glucocorticoids


- ▶ corticosteroid
- ▶ produced in adrenal cortex
- ▶ inactivation in liver





# Glucocorticoids

- ▶ corticosteroid
- ▶ produced in adrenal cortex
- ▶ inactivation in liver
- ▶ excites gluconeogenesis  
from fat and proteins  
=> high blood concentration of  
glucose, amino acids,  
fatty acids



# Methylprednisolone



Systematic name: (1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadeca-3,6-dien-5-one

Class: synthetic **glucocorticoid**

Desired effects: anti-inflammatory  
metabolism  
immune responses

Side effects:	hyperglycemia (high blood sugar) weight gain decreased resistance to infection swelling of face cardiac insufficiency fluid and sodium retention	glaucoma osteoporosis psychosis osteoporosis increased eye pressure fatal chicken pox viral
---------------	---	--

course

hypertension (high blood pressure)

edema

# Methylprednisolone

Systematic name: (1S,2R,8S,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,8,15-trimethyltetracyclo[8.7.0.0<sup>2,7</sup>.0<sup>11,15</sup>]heptadeca-3,6-dien-5-one

Class:

synthetic glucocorticoid

Desired effects:

Applications:

allergic and autoimmune reactions  
skin diseases  
anaphylactic shock / asthma  
cerebral edema  
spinal chord injuries (in USA)

Side effects:

decreased resistance to infection  
swelling of face  
cardiac insufficiency  
fluid and sodium retention

glaucoma  
osteoporosis  
psychosis  
increased eye pressure  
fatal chicken pox viral

course

hypertension (high blood pressure)


edema



# Glucocorticoid Receptor (GR)

- ▶ regulates genes controlling the development, metabolism, and immune response
- ▶ receptor to which glucocorticoids bind


DNA





# Tyrosine aminotransferase (TAT)

- ▶ plays a role in amino acid metabolism (tyrosine) in liver
- ▶ is regulated by activated GR





# The study

1. intravenous doses of **MPL** into **rats**
  - ▶ 10 mg/kg, 50 mg/kg
2. measurement of **concentrations**
  - ▶ mRNA + protein of **GR**
  - ▶ mRNA + protein of **TAT**
3. fitting two different models
4. publishing

# The study

**Table II.** Pharmacodynamic Parameters Estimated by the Maximum Likelihood Method

Parameters (units)	Model A (CV%)	Model B (CV%)
$IC_{50,GRmRNA}$ (nmole/L per mg protein)	50.7 (63)	— <sup>c</sup>
$S_{max,GRmRNA}$	— <sup>c</sup>	2.1 (42)
$SC_{50,GRmRNA}$ (nmole/L per mg protein)	— <sup>c</sup>	36.9 (85)
$k_{syn,GRmRNA}$ (fmole/g per hr)	1.90 <sup>a</sup> /1.77 <sup>b</sup>	1.03 <sup>a</sup> /0.96 <sup>b</sup>
$k_{dgr,GRmRNA}$ (hr <sup>-1</sup> )	0.11 (35)	0.06 (41)
$k_{on}$ (L/nmole per hr)	$4.87 \cdot 10^{-4}$ (25)	$4.04 \cdot 10^{-4}$ (13)
$k_{syn,GR}$ (nmole GR/L per mg protein per fmole GR mRNA/g per hr)	1.52 <sup>a</sup> /2.10 <sup>b</sup>	3.05 <sup>a</sup> /4.19 <sup>b</sup>
$k_{dgr,GR}$ (hr <sup>-1</sup> )	0.07 (17)	0.14 (38)
$R_f$	0.46 (23)	0.24 (63)
$k_T$ (hr <sup>-1</sup> )	2.03 (63)	0.39 (43)
$k_{re}$ (hr <sup>-1</sup> )	0.36 (21)	0.37 (37)
$k_N$ (hr <sup>-1</sup> )	0.50 (17)	1.41 (33)
$mRNA_{TAT,0}$ (pmole/g)	0.11 <sup>a</sup> /0.07 <sup>b</sup> (9,7)	0.11 <sup>a</sup> /0.07 <sup>b</sup> (9,7)
$EF_1$ (pmole TAT mRNA/g per nmole GR per mg protein)	$1.58 \cdot 10^{-5}$ (37)	$1.52 \cdot 10^{-5}$ (135)
$k_{dgr,TATmRNA}$ (hr <sup>-1</sup> )	1.3 (32)	1.7 (43)
$\gamma_1$	1.9 (15)	2.0 (13)
$TAT_0$ (ΔA/mg protein)	0.07 (11 <sup>a</sup> /7 <sup>b</sup> )	0.07 (7 <sup>a</sup> /8 <sup>b</sup> )
$EF_2$ (ΔA/mg of protein per pmole of TAT mRNA/g)	2.21 (17)	2.87 (21)
$k_{dgr,TAT}$ (hr <sup>-1</sup> )	0.99 (16)	1.41 (20)
$\gamma_2$	0.82 (9)	0.79 (9)


<sup>a</sup>Results for 10 mg/kg MPL.

<sup>b</sup>Results for 50 mg/kg MPL.


<sup>c</sup>Not applicable.

# Two Models

Model A  
Inhibition -  $k_{syn}$



Model B  
Stimulation -  $k_{dgr}$






# Part 0 - Pharmacokinetics

*Model A*  
Inhibition -  $k_{syn}$

*Model B*  
Stimulation -  $k_{deg}$



$D = [\text{drug in plasma}]$




# Part 1 - GR cycle

Model A  
Inhibition -  $k_{syn}$

$\frac{k_{syn,GRmRNA}}{DR(N) \text{ } (-)}$

Model B  
Stimulation -  $k_{gr}$


$\frac{k_{dgr,GRmRNA}}{DR \text{ } (+)}$



R = recceptor protein

DR = drug bonded on recceptor


DR(N) = DR in nucleus



# Part 2 - TAT cycle


*Model A*  
Inhibition -  $k_{in}$

*Model B*  
Stimulation -  $k_{st}$




**TC** = transcription compartment  
**EF** = transcription factor

# Two Models






# Pharmacokinetics (descriptive)



- ▶  $D_0$ : intravenous drug administration
- ▶ CL: Clearance
- ▶  $k_{12}, k_{21}$ : volume diffusion parameter

# Pharmacokinetics (descriptive)



$$\frac{dA_p}{dt} = -(CL/V_c) \cdot A_p - k_{12} \cdot A_p + k_{21} \cdot A_t$$

$$\frac{dA_t}{dt} = k_{12} \cdot A_p - k_{21} \cdot A_t$$

# Pharmacokinetics (descriptive)


reminder -  $\forall$  species i:

$$\frac{d}{dt}X_i = \sum_j s_{i,j} \cdot r_j(X,p)$$

$$\frac{d}{dt}X = S \cdot R(X,p)$$

$$\frac{dA_p}{dt} = -\overset{(1)}{(CL/V_c) \cdot A_p} - k_{12} \cdot A_p + k_{21} \cdot A_t$$


$$\frac{dA_t}{dt} = k_{12} \cdot A_p - k_{21} \cdot A_t$$



# Pharmacokinetics (descriptive)

$$\frac{d}{dt} X = S \cdot R(X, p)$$

$$\begin{aligned} \frac{dA_p}{dt} &= -\overset{(1)}{\boxed{(CL/V_c) \cdot A_p}} - \overset{(2)}{\boxed{k_{12} \cdot A_p}} + \overset{(3)}{\boxed{k_{21} \cdot A_t}} \\ \frac{dA_t}{dt} &= \overset{(2)}{\boxed{k_{12} \cdot A_p}} - \overset{(3)}{\boxed{k_{21} \cdot A_t}} \end{aligned}$$






# Pharmacokinetics (descriptive)

$$\frac{d}{dt} X = \mathbf{S} \cdot R(X, p)$$

$$\frac{dA_p}{dt} = \boxed{-(CL/V_c) \cdot A_p} \boxed{-k_{12} \cdot A_p} \boxed{+k_{21} \cdot A_t}$$

$$\frac{dA_t}{dt} = k_{12} \cdot A_p \boxed{-k_{21} \cdot A_t}$$




# Pharmacokinetics (descriptive)

$$\frac{d}{dt} X = S \cdot R(X, p)$$

$$S = \begin{matrix} & \begin{matrix} (1) & (2) & (3) \end{matrix} \\ \begin{pmatrix} -1 \\ 0 \end{pmatrix} & \begin{matrix} -1 & +1 \\ +1 & -1 \end{matrix} \end{matrix}$$


$$\frac{dA_p}{dt} = \begin{matrix} & (1) & (2) & (3) \\ \begin{bmatrix} -(CL/V_c) \cdot A_p - k_{12} \cdot A_p + k_{21} \cdot A_t \end{bmatrix} \end{matrix}$$

$$\frac{dA_t}{dt} = \begin{matrix} (2) & (3) \\ \begin{bmatrix} k_{12} \cdot A_p - k_{21} \cdot A_t \end{bmatrix} \end{matrix}$$




# Results / Comparison

paper




reproduction



# Part 0 - Parmacokinetics

Model A  
Inhibition -  $I_{GR}$

Model B  
Stimulation -  $I_{GR}$



**D = [drug in plasma]**




# Part 1 - GR cycle

**Model A**  
Inhibition -  $k_{syn}$

$\frac{k_{syn,GRmRNA}}{DR(N) \text{ } (-)}$

**Model B**  
Stimulation -  $k_{gr}$


$\frac{k_{dgr,GRmRNA}}{DR \text{ } (+)}$



**R** = receptor protein

**DR** = drug bonded on receptor

**DR(N)** = DR in nucleus



# Part 1 - GR cycle


$$\begin{pmatrix} +1 & -1 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -1 & +1 & +1 & -1 & 0 & 0 \\ 0 & 0 & +1 & 0 & 0 & 0 & -1 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & +1 & -1 \end{pmatrix}$$

$$\frac{dmRNA_{GR}}{dt} = k_{syn,GRmRNA} \cdot \left( 1 - \frac{DR(N)}{IC_{50,GRmRNA} + DR(N)} \right) - k_{dgr,GRmRNA} \cdot mRNA_{GR}$$

$$\frac{dR}{dt} = -k_{on} \cdot D \cdot R + k_{syn,GR} \cdot mRNA_{GR} + (R_f \cdot k_{re}) \cdot DR(N) - k_{dgr,GR} \cdot R$$

$$\frac{dDR}{dt} = k_{on} \cdot D \cdot R - k_T \cdot DR$$

$$\frac{dDR(N)}{dt} = k_T \cdot DR - k_{re} \cdot DR(N)$$



# Part 1 - GR cycle

$$\begin{pmatrix} +1 & -1 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & -1 & +1 & +1 & -1 & 0 & 0 \\ 0 & 0 & +1 & 0 & 0 & 0 & -1 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & +1 & -1 \end{pmatrix}$$

$$\frac{dmRNA_{GR}}{dt} = k_{syn,GRmRNA} \cdot \left( 1 - \frac{DR(N)}{IC_{50,GRmRNA} + DR(N)} \right)$$


$$-k_{dgr,GRmRNA} \cdot mRNA_{GR}$$

$$\frac{dR}{dt} = -k_{on} \cdot D \cdot R + k_{syn,GR} \cdot mRNA_{GR} + (R_f \cdot k_{re}) \cdot DR(N)$$

$$-k_{dgr,GR} \cdot R$$


$$\frac{dDR}{dt} = k_{on} \cdot D \cdot R - k_T \cdot DR$$

$$\frac{dDR(N)}{dt} = k_T \cdot DR - k_{re} \cdot DR(N)$$




# Results / Comparison

paper



reproduction






# Part 1 - GR cycle

**Model A**  
Inhibition -  $k_{syn}$

$\frac{k_{syn,GRmRNA}}{DR(N) \text{ } (-)}$

**Model B**  
Stimulation -  $k_{gr}$


$\frac{k_{dgr,GRmRNA}}{DR \text{ } (+)}$



**R** = recceptor protein

**DR** = drug bonded on recceptor


**DR(N)** = DR in nucleus



# Part 2 - TAT cycle

*Model A*  
Inhibition -  $k_{deg}$

*Model B*  
Stimulation -  $k_{deg}$



TC = transcription compartment  
EF = transcription factor




# Part 1 - GR cycle



$$\frac{dTC}{dt} = k_N \cdot DR(N) - k_N \cdot TC$$

$$\frac{dmRNA_{TAT}}{dt} = EF_1 \cdot TC^{\gamma_1} - k_{dgr, TATmRNA} \cdot (mRNA_{TAT} - mRNA_{TAT,0})$$

$$\frac{dTAT}{dt} = EF_2 \cdot (mRNA_{TAT} - mRNA_{TAT,0})^{\gamma_2} - k_{dgr, TAT} \cdot (TAT - TAT_0)$$




# Part 1 - GR cycle

$$\frac{dTC}{dt} = k_N \cdot DR(N) - k_N \cdot TC$$

$$\frac{dmRNA_{TAT}}{dt} = EF_1 \cdot TC^{\gamma_1} - k_{dgr,TATmRNA} \cdot (mRNA_{TAT} - mRNA_{TAT,0})$$


$$\frac{dTAT}{dt} = EF_2 \cdot (mRNA_{TAT} - mRNA_{TAT,0})^{\gamma_2} - k_{dgr,TAT} \cdot (TAT - TAT_0)$$






# Results / Comparison

paper



reproduction






# Conclusion

- ▶ Model describes the measured data good
- ▶ Model gives a description of pharmacodynamics and pharmacokinetics of the pharmacological pathway of methyprednisolon
- ▶ Results are reproducible with the model parameters

# Conclusion

- Model uses different approaches / is inconsistent / is badly described



$$\frac{dmRNA_{GR}}{dt} = k_{\text{syn},GRmRNA} \cdot \left( 1 - \frac{DR(N)}{IC_{50,GRmRNA} + DR(N)} \right) - k_{\text{dgr},GRmRNA} \cdot mRNA_{GR}$$


$$\frac{dR}{dt} = -k_{\text{on}} \cdot D \cdot R + k_{\text{syn},GR} \cdot mRNA_{GR} + (R_f \cdot k_{re}) \cdot DR(N) - k_{\text{dgr},GR} \cdot R$$

$$\frac{dDR}{dt} = k_{\text{on}} \cdot D \cdot R - k_T \cdot DR$$

$$\frac{dDR(N)}{dt} = k_T \cdot DR - k_{re} \cdot DR(N)$$

# Conclusion

- Model uses different approaches / is inconsistent / is badly described



$$\frac{dmRNA_{\text{GR}}}{dt} = k_{\text{syn,GRmRNA}} \left( 1 - \frac{DR(N)}{IC_{50,GRmRNA} + DR(N)} \right) - k_{\text{dgr,GRmRNA}} \cdot mRNA_{\text{GR}}$$

$$\frac{dR}{dt} = -k_{\text{on}} \cdot D \cdot R + k_{\text{syn,GR}} \cdot mRNA_{\text{GR}} + (R_f \cdot k_{\text{re}}) \cdot DR(N) - k_{\text{dgr,GR}} \cdot R$$

$$\frac{dDR}{dt} = k_{\text{on}} \cdot D \cdot R - k_{\text{T}} \cdot DR$$

$$\frac{dDR(N)}{dt} = k_{\text{T}} \cdot DR - k_{\text{re}} \cdot DR(N)$$

# Conclusion

- Model uses different approaches / is inconsistent / is badly described

$$\frac{dR}{dt} = -k_{\text{on}} \cdot D \cdot R + k_{\text{syn,GR}} \cdot mRNA_{\text{GR}} + (R_f \cdot k_{\text{re}}) \cdot DR(N) - k_{\text{dgr,GR}} \cdot R$$

$$\frac{dTAT}{dt} = EF_2 \cdot (mRNA_{\text{TAT}} - mRNA_{\text{TAT},0})^{\gamma_2} + k_{\text{dgr,TAT}} \cdot (TAT - TAT_0)$$



# Conclusion

- ▶ Model uses different approaches / is inconsistent / is badly described
- ▶ Model is chosen numerically bad

$$\frac{dTAT}{dt} = EF_2 \cdot (mRNA_{TAT} - mRNA_{TAT,0})^{\gamma_2} \quad 0.82$$

# Conclusion

- ▶ Model uses different approaches / is inconsistent / is badly described
- ▶ Model is chosen numerically bad
- ▶ Units are a mess

$k_{\text{syn,GR}}$  (nmole GR/L per mg protein  
per fmole GR mRNA/g per hr)

$TAT_0$  ( $\Delta A$ /mg protein)



# Conclusion

- ▶ Model uses different approaches / is inconsistent / is badly described
- ▶ Model is chosen numerically bad
- ▶ Units are a mess
- ▶ Different parameter for different doses

# Conclusion

- ▶ Model describes the measured data good
- ▶ Model gives a description of pharmacodynamics and pharmacokinetics of the pharmacological pathway of methyprednisolon
- ▶ Results are reproducible with the model parameters
- ▶ Model uses different approaches / is inconsistent / is badly described
- ▶ Model is chosen numerically bad
- ▶ Units are a mess
- ▶ Different parameter for different doses

**FIN**



**THANK YOU FOR THE FISH**





# Implementation in Matlab

```
function [T, Y] = myMPLDosing_single(y0, p, duration)
    % initiale Parameter festlegen
    weight = 0.213; % subject weight
    Tspan = [ 0 duration ]; % [min]

    RTol = 1e-4; % relative tolerance
    ATol = 1e-6; % absolute tolerance
    options = odeset('RelTol', RTol, 'AbsTol', ATol, 'NonNegative', [1 2]);

    [T, Y] = ode15s(@(t, y) f(t, y, p), Tspan, y0, options);
end

%% y' = f(t, y, p)
% A_p' = -CL/V_C * A_p - k_12 * A_p + k_21 * A_t
% A_t' = k_12 * A_p - k_21 * A_t
function y_d = f(~, y, p)
    A_p = y(1); A_t = y(2);
    S = [ -1 -1 1 ; ...
          0 1 -1 ];
    rCoeff = p .* [ A_p A_p A_t ];
    y_d = S * rCoeff;
end
```